Increased Epicardial Adipose Tissue Volume Correlates With Cardiac Sympathetic Denervation in Patients With Heart Failure

Valentina Parisi, Giuseppe Rengo, Pasquale Perrone-Filardi, Gennaro Pagano, Grazia Daniela Femminella, Stefania Paolillo, Laura Petraglia, Giuseppina Gambino, Aurelio Caruso, Maria Gabriella Grimaldi, Francesco Baldascino, Maria Nolano, Andrea Elia, Alessandro Cannavo, Antonio De Bellis, Enrico Coscioni, Teresa Pellegrino, Alberto Cuocolo, Nicola Ferrara, Dario Leosco

Rationale: It has been reported that epicardial adipose tissue (EAT) may affect myocardial autonomic function.

Objective: The aim of this study was to explore the relationship between EAT and cardiac sympathetic nerve activity in patients with heart failure.

Methods and Results: In 110 patients with systolic heart failure, we evaluated the correlation between echocardiographic EAT thickness and cardiac adrenergic nerve activity assessed by 123I-metaiodobenzylguanidine (123I-MIBG). The predictive value of EAT thickness on cardiac sympathetic denervation (123I-MIBG early and late heart:mediastinum ratio and single-photon emission computed tomography total defect score) was tested in a multivariate analysis. Furthermore, catecholamine levels, catecholamine biosynthetic enzymes, and sympathetic nerve fibers were measured in EAT and subcutaneous adipose tissue biopsies obtained from patients with heart failure who underwent cardiac surgery. EAT thickness correlated with 123I-MIBG early and late heart:mediastinum ratio and single-photon emission computed tomography total defect score, but not with left ventricular ejection fraction. Moreover, EAT resulted as an independent predictor of 123I-MIBG early and late heart:mediastinum ratio and single-photon emission computed tomography total defect score and showed a significant additive predictive value on 123I-MIBG planar and single-photon emission computed tomography results over demographic and clinical data. Although no differences were found in sympathetic innervation between EAT and subcutaneous adipose tissue, EAT showed an enhanced adrenergic activity demonstrated by the increased catecholamine levels and expression of catecholamine biosynthetic enzymes.

Conclusions: This study provides the first evidence of a direct correlation between increased EAT thickness and cardiac sympathetic denervation in heart failure. (Circ Res. 2016;118:1244-1253. DOI: 10.1161/CIRCRESAHA.115.307765.)

Key Words: echocardiography ■ epicardial adipose tissue ■ heart failure ■ MIBG ■ nuclear radiology ■ sympathetic nervous system

Cardiac sympathetic nervous system (SNS) hyperactivity is a specific hallmark of heart failure (HF)\(^1\)\(^-\)\(^6\) and represents a compensatory response in the initial phase of this syndrome aimed at enhancing myocardial inotropism and preserving cardiac output. However, in the long term, this mechanism promotes maladaptive cardiac remodeling, life-threatening ventricular arrhythmias, worsening symptoms, and increased mortality.\(^1\)\(^-\)\(^6\) In the failing heart, a defect of neuronal norepinephrine reuptake

In This Issue, see p 1185
Editorial, see p 1189

caused by post-transcriptional downregulation of the cardiac norepinephrine transporter\(^7\)\(^-\)\(^11\) leads to an increase in norepinephrine concentration in the sympathetic synapses. This is responsible for impaired myocardial β-adrenergic receptor system and functional and anatomic sympathetic denervation of the heart.\(^12\)\(^,\)\(^13\)
Epicardial Fat and SNS Activity in Heart Failure

Nonstandard Abbreviations and Acronyms

- EAT: epicardial adipose tissue
- H/M: heart:mediastinum
- HF: heart failure
- HRV: heart rate variability
- 123I-MIBG: 123I-metaiodobenzylguanidine
- LV: left ventricular
- LVEF: left ventricular ejection fraction
- NYHA: New York Heart Association
- SCAT: subcutaneous adipose tissue
- SNS: sympathetic nervous system
- TDS: total defect score

Furthermore, experimental studies in severe HF animals have demonstrated that prolonged exposure of high plasma norepinephrine concentration causes reduced myocardial expression of neurotrophic factors such as the nerve growth factor, thus resulting in cardiac sympathetic fiber loss.14 Although it is widely recognized that cardiac SNS hyperactivity in HF is mainly mediated by norepinephrine-releasing neurons and by circulating norepinephrine and epinephrine, other mechanisms may contribute to SNS hyperactivation. For example, the adipose tissue, particularly the visceral fat depots, may stimulate central SNS activity through dysregulated adipokine production and secretion.15-17 In addition, experimental studies have recently demonstrated that adipocytes produce and secrete both norepinephrine and epinephrine,18 therefore, suggesting that the sympathetic fibers within adipose tissue are not the only source of catecholamines. Epicardial adipose tissue (EAT) is the visceral fat depot of the heart and represents a source of several adipocytokines and other bioactive molecules.19-20 Because of its proximity to the myocardium and absence of fascial boundaries, EAT directly influences myocardial homeostasis through vasocrine and paracrine mechanisms. In fact, abnormalities of EAT secretory properties are implicated in the development of pathological conditions, including coronary atherosclerosis, left ventricular (LV) hypertrophy, LV diastolic dysfunction, and aortic stenosis.20-26 Moreover, EAT contains abundant adrenergic and cholinergic nerves that interact with the extrinsic nervous system.

The relationship between EAT and cardiac SNS activity in HF has not been adequately explored yet. Therefore, in the present study, we have investigated the correlation between EAT and cardiac adrenergic nerve activity in patients with HF caused by LV systolic dysfunction.

Methods

Study Population

The patient population included 110 consecutive patients with HF caused by ischemic and nonischemic causes enrolled between January 2013 and November 2014 at the HF clinic of Federico II University of Naples. All patients were clinically referred to cardioverter defibrillator implantation, as indicated for either primary or secondary prevention. Before cardioverter defibrillator implantation and within 7 days from enrollment, patients underwent 123I-metaiodobenzylguanidine (123I-MIBG) planar and single-photon emission computed tomography (SPECT) imaging and a 2D-echocardiographic study. We used the following inclusion criteria: (1) left ventricular ejection fraction (LVEF) ≤50% during optimized medical therapy; (2) stable hemodynamic conditions; (3) no acute coronary syndromes in the past 6 months. We excluded patients with hemodynamic instability, moderate to severe valvular disease, atrial fibrillation or flutter, ventricular paced rhythm, myocardial inflammatory diseases, and suboptimal echocardiographic image quality. At the time of enrollment, all patients underwent a complete clinical examination and blood withdrawal for routine biochemical determinations. Demographic data including age, sex, HF medications, cardiovascular risk factors and the presence of comorbidities were also collected. We also included a group of 44 healthy subjects matched for age (66.8±12.5), sex (male, 85%), and body mass index (26.5±1.7). In these control subjects, we excluded the presence of cardiovascular diseases, cardiovascular risk factors, renal diseases, systemic inflammatory diseases, or any cardiovascular drug therapy. This group served as a control for echocardiographic EAT thickness comparisons. The study was approved by the local Ethics Committee. All procedures performed in the study were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards and conform to the Declaration of Helsinki on human research. All patients included in the study gave written informed consent after receiving an accurate explanation of the study protocol and of the potential risks related to the procedures adopted by the study.

Echocardiographic Study

Echocardiograms were performed by a VIVID E9 (GE Healthcare) machine, according to standard techniques. Echocardiographic images were recorded through an EchoPAC Clinical Workstation Software (GE Healthcare). In all HF patients and in control subjects, measurements of EAT thickness were obtained from a parasternal long-axis view. EAT thickness was measured at end systole, perpendicularly to the free wall of the right ventricle in 3 cardiac cycles as previously described by Iacobellis and Willens.27 Measurements of EAT thickness were performed offline by 2 independent operators. The average value from 3 cardiac cycles was used for the statistical analysis. The intraobserver and interobserver correlation coefficients were tested.

123I-MIBG Myocardial Scintigraphy

All patients with HF underwent planar and SPECT 123I-MIBG cardiac imaging according to the recommendations of the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology,28 as previously described in detail.29 We also included data from a control group of 10 subjects who underwent cardiac 123I-MIBG scintigraphy to rule out a disease of the adrenal medulla. An activity of 111 MBq (3.0-5.0 MBq) (Coviden, Mallinckrodt) was intravenously administered 1-2 hours after thyroid blockade by oral administration of 300 mg of potassium perchlorate. Ten-minute planar images of the thorax in standard anterior view (256x256 matrix) were performed 15 minutes (early image) and 3 hours and 50 minutes (late image) after tracer administration. Four hours after tracer administration, a SPECT study (step and shoot mode, 90 projections, imaging time 30 minutes, 64x64 matrix) was performed. Imaging was performed using a dual-head camera system (SkyLight, Philips) equipped with a low-energy, parallel-hole, high-resolution collimator, and the camera peaked at 159 keV with a symmetrical 20% energy window. From planar images, the heart:mediastinum (H/M) ratio was calculated by dividing the mean counts per pixel within the myocardium by the mean counts per pixel within the mediastinum. Using dedicated postprocessing software on a dedicated workstation (Philips), the cardiac region of interest for assessment was polygonal in shape and drawn manually over the myocardium including the LV cavity on the planar MIBG images. Care was taken to exclude lung and liver from the myocardial region of interest. The mediastinal region of interest with a square shape was placed on the upper half of the mediastinum and had a size of 7x7 pixels. The location of the mediastinal region of interest was determined using as landmarks the lung apex, the upper cardiac border and the mediastinal contours of the lungs. H/M ratios were computed for early and late planar imaging by dividing the mean counts per pixel within the myocardium by the mean counts per pixel within the mediastinum. The MIBG washout...
rate was calculated using the following formula: [(early heart counts per pixel−early mediastinum counts per pixel)−[late heart counts per pixel−pixel decay-corrected−late mediastinum counts per pixel−pixel decay corrected]/(early heart counts per pixel−early mediastinum counts per pixel)]×100. SPECT studies were processed with filtered back-projection and reconstructed into standard long-axis and short-axis images, perpendicular to the heart axis. From SPECT images, the defect score was calculated by assessing the patient’s segmental tracer uptake score using the 17-segment model. Each myocardial segment was scored according to the following tracer uptake scale: 0 normal, 1 mildly reduced, 2 moderately reduced, 3 severely reduced, and 4 no uptake. The total defect score (TDS) was calculated as the sum of the segmental tracer uptake scores (summed score) and separately for each vascular territory. Images interpretation was done by consensus of 2 independent readers. Intra- and interobserver reproducibility was excellent, thus confirming our recent results from a low-dose MIBG cardiac imaging protocol in patients with HF. No patient was excluded for poor quality of MIBG images.

Heart Rate Variability Analysis of Cardiac Parasympathetic Activity Heart rate variability (HRV) was assessed from 24-hour ambulatory Holter ECG monitoring (Mars System; GE Healthcare). To evaluate cardiac parasympathetic activity, we used the root-mean-square of the successive normal sinus RR interval difference and the percentage of successive normal sinus RR intervals >50 ms (pNN50) in the time domain HRV, and the high-frequency oscillation in the spectral HRV domain.

Tissues Collection and Norepinephrine and Epinephrine Determination Of 110 patients with HF enrolled into the study, 16 underwent cardiac surgery for coronary artery bypass grafting. From this group of patients, we obtained EAT and subcutaneous adipose tissue (SCAT) samples during cardiac intervention. EAT and SCAT biopsy samples (average 0.1–0.5 g) were obtained before the initiation of cardiopulmonary bypass. EAT biopsies were taken near the proximal right coronary artery, whereas SCAT samples were obtained from the chest. Tissue sample were homogenized with tissue homogenizer (Ultra-Turrax, IKA T10) in 1 mL of 0.01 mol/L HCl, 1 mmol/L EDTA, and 4 mmol/L sodium metabisulfite, stored in ice for 1 hour, and centrifuged for 15 minutes (13100g, 4°C), the supernatants were used for the catecholamines determination by enzyme immunoassay.

Norepinephrine and epinephrine were measured in EAT, SCAT, and plasma. All measurements were performed using 2-CAT Research RIA kits (Labor Diagnostika Nord, Nordhorn, Germany) according to the manufacturer’s protocol.

RNA Isolation and Absolute Quantification of Tyrosine Hydroxylase, Dopamine-β-Hydroxylase, and Phenylethanolamine N-Methyltransferase mRNA Levels by Real-Time Polymerase Chain Reaction Using SYBR Green Total RNA was isolated from EAT and SCAT samples with RNeasy Lipid Tissue Mini Kit (Qiagen) according to the manufacturer’s instructions. The purity and concentration of isolated RNA were measured with NanoDrop (Jenway, Genova, NANO). Reverse transcription was performed in 20 μL of reaction mixture containing 180 ng of total RNA, with High Capacity cDNA Reverse Transcription Kits (Applied Biosystems) according to the manufacturer’s protocol. Absolute mRNA levels of tyrosine hydroxylase (TH), dopamine-β-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT) were evaluated by quantitative real-time polymerase chain reaction on thermocycler q5 Multicolor (Bio-Rad). The amounts of mRNA were determined by amplification of 18 ng of cDNA target using q SYBR Green Supermix (Bio-Rad) according to manufacturer’s protocols. Reactions also contained 300 nmol of each the forward and reverse primers: PNMT forward primer, 59-GCA GCC ACT TTG AGG ACA TCA-39; PNMT reverse primer, 59-GGC TGT ACA TGC TCC AGT TGA A-39; TH forward primer, 59-CGG ATG AGG AAA TTG AGA AGC T-39; TH reverse primer, 59-TCT GCT TAC ACA GCC CGA ACT-59; DBH forward primer 59-GTGGTACATTAAGGAGCTTCAAAAG-39, reverse primer 59-GGCTCATGTCCTGCGGT-39. GAPDH rRNA was used as endogenous control.

Real-time polymerase chain reaction conditions were a typical 2-step real-time polymerase chain reaction protocol, 2 minutes at 95°C, followed by 40 cycles of denaturation for 15 seconds at 95°C and annealing/extension for 30 seconds at 60°C. The polymerase chain reaction products were quantified with an automatic sequence detection system at each step of amplification using the Optical System Software (version 2.1; Bio-Rad).

Immunoblotting SCAT and EAT samples were weighed (±15 mg) and lysed in 150 μL of RIPA buffer with protease and phosphatase inhibitors cocktail (Roche). Protein concentrations in all lysates were measured using a dye-binding protein assay kit (Bio-Rad) and a spectrophotometer reader (Bio-Rad) at a wavelength of 750 nm. Protein levels of TH were detected by protein immunoblotting using a 1:1000 anti-rabbit IgG (Millipore AB152); PNMT was detected using 1:1000 anti-mouse IgG (WH0005409M6; Sigma); GAPDH was used as internal loading control. Secondary antibodies were purchased from ImmunoReagents, Inc., Raleigh. Bands were visualized by enhanced chemiciluminescence (ECL; Millipore Immobilon, Western Chemiluminescent HRP Substrate) and were quantified using densitometry (Chemidoc; Bio-Rad).

Immunohistochemical Procedures EAT and SCAT samples were frozen at −80°C and cut in 50-μm consecutive sections using a freezing microtome (Leica 2000R, Germany). Free-floating sections were processed by means of indirect immunofluorescence technique using rabbit polyclonal antibodies against TH (Millipore AB152, 1:1000) to mark sympathetic nerve fibers. In both EAT and SCAT, most of the sympathetic nerve fibers were localized along vessels with few scattered fibers randomly distributed. Therefore, to quantify vascular innervation, digital images of all vessels found in 42 stained sections were acquired using nonlaser confocal microscopy (Aptomite confocal system; Zeiss, Oberkochen, Germany). The highest number of fibers running along the vessel and intercepting a superimposed line perpendicular to the major axis of the vascular structure were counted. We measured the total number of intercepts for each vessel and the nerve density calculated as the mean number of intercepts per vessel caliber in μm (fibers/μm).

A single operator blindly performed all the measurements.

Statistical Analysis Continuous variables were expressed as means±SD and compared by the use of Student t test (normally distributed) or as median±interquartile range value and compared by the use of Mann–Whitney U test (not normally distributed), as appropriate. Normality of data distribution was evaluated using the Kolmogorov–Smirnov test. Categorical variables were expressed as proportion and compared by use of χ2 test. Pearson correlation coefficient was calculated to assess correlation between data. To determine the independent predictors of 123I-MIBG uptake, late H/M, and late SPECT, variables achieving P<0.10 on univariate analysis (age, sex, LVEF, New York Heart Association [NYHA] class, body mass index, ischemic status, diabetes mellitus, hypertension, and dyslipidemia, and EAT thickness) were then included in a multivariate linear regression analysis. The additive predictive value of EAT thickness on 123I-MIBG planar and SPECT results was assessed by the increase of r2 in a 3-step linear regression modeling. The first step consisted of fitting a multivariate model 1 of age, sex, NYHA class, H/F of ischemic cause, diabetes mellitus, hypertension, and dyslipidemia, and EAT thickness were then included in a multivariate linear regression analysis. The additive predictive value of EAT thickness on 123I-MIBG planar and SPECT results was assessed by the increase of r2 in a 3-step linear regression modeling. The first step consisted of fitting a multivariate model 1 of age, sex, NYHA class, H/F of ischemic cause, diabetes mellitus, hypertension, and dyslipidemia. Then, LVEF was included in the second step. Next, EAT thickness was included in the third step. The change in overall r2 was used to assess the increase in predictive power after the addition of each variable. All data were collected in an Excel database and analyzed by SPSS version 19.0 (SPSS, Inc., Chicago, IL). Statistical significance was accepted at P<0.05.
Results

Patient Characteristics

Table 1 illustrates demographic, clinical, echocardiographic, and $^{123}$I-MIBG characteristics of the HF population. The mean age was 64.74±10.50 years and 85.5% of patients were men. The majority of the patients were in NYHA class II (60%) and III (36.4%). Ischemic cause of HF was recognized in 72% of cases. Forty-two percent of the patients were diabetics, 74% had hypertension, 45% were smokers, and 72% had dyslipidemia. The majority of the patients were on optimal HF drug therapy. Mean LVEF was 38.1±9.3%, and mean EAT thickness was 8.6±2.55 mm. At $^{123}$I-MIBG scintigraphy, mean early and late H/M were significantly lower than in healthy controls (early H/M, 1.76±0.23 versus 2.23±0.18; P<0.001; late H/M, 1.57±0.25 versus 2.14±0.19; P<0.0001; Online Figure I). In the patients with HF, the washout rate was 10.83±10.04, and the mean SPECT TDS was 35.6±16.8. Overall, these data are consistent with cut-off data previously reported by our group and others10,11 and indicate a significant cardiac sympathetic denervation. In patients with HF, the EAT thickness value was significantly higher than in controls (8.6±2.55 versus 4.7±1.24 mm; P<0.001), which is consistent with the increase in LV end-diastolic mass (202±48 versus 122±26 g; P<0.01).24 The reproducibility for echocardiographic EAT thickness assessment was excellent (intraobserver, 0.897; interobserver, 0.921).

Correlation Between Echocardiographic EAT Thickness and Cardiac $^{123}$I-MIBG Data: Multivariable Predictors of Cardiac Sympathetic Denervation

EAT thickness showed a weak, although significant, correlation with planar $^{123}$I-MIBG parameters (early and late H/M), whereas a more evident correlation was found with $^{123}$I-MIBG SPECT TDS (Figure 1; Online Table I). There was no correlation between EAT and LVEF (Online Table I). Noteworthy, LVEF significantly correlated with late H/M (r = 0.388; P<0.0001), but not with early H/M, washout rate and SPECT TDS (Online Table II).

Multivariate linear regression analyses were used to assess the predictors of $^{123}$I-MIBG planar and SPECT parameters (Table 2). The EAT thickness resulted as a significant independent predictor of $^{123}$I-MIBG early and late H/M, and SPECT TDS. LVEF and NYHA class significantly predicted both early and late H/M, but not SPECT TDS. The incremental predictive value of EAT thickness on $^{123}$I-MIBG planar and SPECT parameters was evaluated from the increase of $r^2$ in a 3-step linear regression modeling (Figure 2). For $^{123}$I-MIBG SPECT TDS (Figure 2A), early (Figure 2B), and late H/M (Figure 2C), the addition of EAT thickness significantly increased global $r^2$ (P<0.05) over model 1 (including age, sex, body mass index, NYHA class, HF of ischemic cause, diabetes mellitus, hypertension, and dyslipidemia) plus LVEF.

EAT Thickness, Cardiac Sympathetic Denervation, and LV Mass

LV mass significantly correlated with both EAT thickness and cardiac sympathetic denervation expressed by $^{123}$I-MIBG late H/M (Figure 3). The significant correlation between EAT and $^{123}$I-MIBG late H/M is illustrated in Figure 1.

Catecholamine Concentration, Catecholamine Biosynthetic Enzymes, and Sympathetic Innervation in EAT and SCAT

EAT and SCAT from patients with HF contained both norepinephrine and epinephrine. More important, EAT showed a 5.6-fold increase of norepinephrine levels when compared with SCAT (0.168±0.026 versus 0.030±0.008 ng/
mL; \( P \leq 0.0001 \) and a 2-fold increase when compared with plasma (0.168±0.026 versus 0.085±0.014 ng/mL; \( P = 0.017 \); Figure 4A). Epinephrine levels were significantly higher in EAT than in SCAT (0.016±0.001 versus 0.008±0.0005 ng/mL; \( P < 0.0001 \)), but lower than in plasma (0.016±0.001 versus 0.06±0.008 ng/mL; \( P < 0.0001 \); Figure 4A).

We investigated whether norepinephrine and epinephrine were produced in adipose tissues. Gene expression of all catecholamine biosynthetic enzymes (TH, DBH, and PNMT) was evident in both EAT and SCAT. mRNA levels of norepinephrine-synthesizing enzymes (TH and DBH) were significantly higher in EAT than in SCAT (8.6-fold and 6.5-fold increase, respectively), which explained the higher norepinephrine concentrations in EAT (Figure 4B). We observed a robust increase of both TH and PNMT protein levels in EAT when compared with SCAT (Figure 4C). The increased protein expression of PNMT in EAT when compared with SCAT was not paralleled by a similar (statistically significant) increase at the mRNA level. We quantified sympathetic nerve fibers in a total number of 45 vessels. We did not find differences in the mean number of fibers per vessel between EAT and SCAT (Figure 4D). On the contrary, the mean vessel diameter in EAT was significantly higher than SCAT vessel diameter (100.37±53.35 and 58.76±30.64 \( \mu \)m, respectively; \( P < 0.001 \)). Therefore, the fiber density per vessel diameter was significantly higher in SCAT than in EAT (\( P < 0.001 \); Figure 4D). Taken together, these data indicate a higher SNS activation in EAT than in SCAT in our HF population.

**EAT and Cardiac Parasympathetic Activity**

HRV data of cardiac parasympathetic activity in patients with HF are reported in Online Table III. Because our evidence indicated a correlation between EAT thickness and cardiac sympathetic nerve derangement, we also explored the relationship between EAT thickness and HRV measures of cardiac parasympathetic activity. In our HF population, EAT thickness did not correlate with pNN50 (Pearson = 0.102; \( P = 0.67 \)), root-mean-square of the successive normal sinus RR interval difference (Pearson = 0.079; \( P = 0.74 \)), and high-frequency oscillation (Pearson = 0.051; \( P = 0.83 \); Online Table IV).
EAT and Cardiac Sympathetic Denervation

EAT represents the visceral fat depot of the heart which covers 80% of the heart’s surface and constitutes 20% of its total weight. It is known that in pathological conditions, EAT may play an unfavorable activity for the heart through production and secretion of proinflammatory and proatherogenic factors. Importantly, recent studies have also indicated a close relationship between EAT and myocardial autonomic function. Many EAT-derived factors can directly modulate the electrophysiological properties and ion currents of myocytes and may promote arrhythmogenesis. Moreover, EAT contains both adrenergic and cholinergic nerves which interact with the extrinsic SNS and para-SNS. Simultaneous activation of these nerve structures within EAT in response to extrinsic nerve activation may enhance triggered activity and facilitate the development of cardiac arrhythmias.

In this study, we have demonstrated that EAT represents an important source of norepinephrine, whose levels are 2-fold higher than those found in plasma. Because of the EAT proximity to the myocardium, the increase in catecholamine content in this tissue could result in a negative feedback on cardiac sympathetic nerves, which are associated with the ventricular myocardium, thus inducing a functional and anatomic denervation of the heart. This hypothesis is supported by our findings showing a direct correlation between EAT thickness and the degree of cardiac sympathetic denervation assessed by cardiac \( ^{123} \)I-MIBG. Therefore, in the context of a widespread SNS hyperactivity in HF, EAT seems to play an additive role in generating the final net effect of cardiac sympathetic denervation. In fact, when the failing myocardium shows depletion of norepinephrine stores because of reduced mechanisms of norepinephrine uptake, circulating catecholamines derived from peripheral organs might play a prominent role in perpetuating the progression of cardiac sympathetic denervation. This is particularly relevant given the importance of cardiac sympathetic nerves in cardiac homeostasis and repair. Importantly, recent studies have also indicated a reduction and secretion of proinflammatory and proatherogenic factors. Simultaneously, the electrophysiological properties and ion currents of myocytes may be affected by these nerve structures within EAT in response to extrinsic nerve activation, leading to arrhythmogenesis. In this regard, it has been demonstrated that cardiac sympathetic denervation completely blocks cardiac regeneration responses after injury in neonatal hearts.

In our analysis, the EAT thickness was an independent predictor of \( ^{123} \)I-MIBG planar and SPECT parameters and provided additional predictive information on cardiac adrenergic nerve activity respect to important demographic, clinical, and LV function parameters. Therefore, assessing EAT thickness in patients with HF may provide surrogate information on the status of cardiac adrenergic derangement, independently from the degree of LV systolic dysfunction and clinical variables. On the contrary, the increase in SNS activity in the EAT did not show any effect on cardiac parasympathetic activity. In this regard, the interaction between cardiac sympathetic and parasympathetic innervation and its effect on cardiac parasympathetic activity has been largely unexplored. The evidence comes only from few experimental studies conducted...
in non-HF animal models, thus avoiding comparisons with our results obtained in the clinical setting.

Overall, these findings seem particularly relevant given the well-recognized importance to assess cardiac sympathetic denervation for the prognostic stratification of patients with advanced HF.

In our patients with HF, the EAT thickness value was significantly higher than in controls consistent with the increase in LV end-diastolic mass. Interestingly, according to previous evidence reporting a relationship between LV hypertrophy and cardiac sympathetic denervation in hypertensive patients, our data indicate a close relationship between EAT,
cardiac sympathetic denervation, and HF severity expressed by the increase of LV mass.

**Catecholamine Production in EAT**

Adipose tissues contain a rich sympathetic innervation. Activation of fat sympathetic fibers leads to the release of catecholamines (mainly norepinephrine), which stimulate fat cell β1, β2, β3, and α2-adrenergic receptors; this mechanism activates or inhibits the lipolysis process. Catecholamines are considered the major regulators of lipolysis and also affect differentiation and proliferation of adipocytes. Catecholamine biosynthesis is catalyzed primarily by TH, DBH, and PNMT enzymes, and recent studies have indicated that the genes of these enzymes are differentially expressed in various adipose tissue depots. The present study reports the first evidence of SNS activation in EAT of patients with HF. In fact, norepinephrine and epinephrine were both present in EAT; moreover, norepinephrine concentrations were higher than in SCAT and plasma. Accordingly, catecholamine signal transduction pathways were also found in EAT with a significant expression of genes (mRNA of TH, DBH, and PNMT) involved in the synthesis of norepinephrine and epinephrine. Notably, catecholamine levels and expression of the enzymes...
involved in catecholamine biosynthesis were significantly higher in EAT than in SCAT. However, based on the histological analysis, SNS hyperactivity found in EAT was not associated with EAT hyperinnervation. These findings may explain, at least in part, the strong correlation between EAT thickness and L-MIBG parameters observed in patients with HF. This supports the hypothesis that increased EAT directly contributes to SNS hyperactivity in the heart that accompanies and fosters myocardial sympathetic denervation and disease progression.

**Limitations**

The current study reports a single-center experience in a relatively small group of patients, and a mid-/long-term follow-up was not available for our study population.

Echocardiographic EAT measurement has several advantages, such as low cost and easy availability, but it also has some limitations because it might not fully reflect the variability of fat thickness or total EAT volume. However, the EAT echocardiographic evaluation has been reported to correlate with magnetic resonance measurements and has an excellent reproducibility, as confirmed in the current study.

The lack of a control group of patients without HF undergoing EAT and SCAT catecholamine measurements represents a limitation of the study. Another question could be raised on whether the EAT and SCAT catecholamine measurements represent the potential use of EAT thickness as an index of cardiac sympathetic denervation and disease progression in HF. These results pave the way for future evaluation on the cardiac sympathetic denervation and represents a source of catecholamines in these adipose tissues.

**Conclusions**

In patients with HF, EAT independently correlates with cardiac sympathetic denervation and represents a source of catecholamine production. SNS activation in EAT might contribute to cardiac sympathetic denervation and disease progression in HF. These results pave the way for future evaluation on the potential use of EAT thickness as an index of cardiac adrenergic nerve activity and prognosis in patients with HF.

**Disclosures**

None.

**References**

Epicardial Fat and SNS Activity in Heart Failure

Increased Epicardial Adipose Tissue Volume Correlates With Cardiac Sympathetic Denervation in Patients With Heart Failure

Valentina Parisi, Giuseppe Rengo, Pasquale Perrone-Filardi, Gennaro Pagano, Grazia Daniela Femminella, Stefania Paolillo, Laura Petraglia, Giuseppina Gambino, Aurelio Caruso, Maria Gabriella Grimaldi, Francesco Baldascino, Maria Nolano, Andrea Elia, Alessandro Cannavo, Antonio De Bellis, Enrico Coscioni, Teresa Pellegrino, Alberto Cuocolo, Nicola Ferrara and Dario Leosco

Circ Res. 2016;118:1244-1253; originally published online February 29, 2016;
doi: 10.1161/CIRCRESAHA.115.307765

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/118/8/1244

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2016/02/29/CIRCRESAHA.115.307765.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
## SUPPLEMENTAL MATERIALS

**Online Table I. Correlation between echocardiographic EAT thickness, and cardiac $^{123}$I-MIBG planar and SPECT data, and LVEF.**

<table>
<thead>
<tr>
<th>$^{123}$I-MIBG planar and SPECT data</th>
<th>EAT</th>
<th>Pearson</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early H/M</td>
<td></td>
<td>-0.305</td>
<td>.001</td>
</tr>
<tr>
<td>Late H/M</td>
<td></td>
<td>-0.332</td>
<td>.0001</td>
</tr>
<tr>
<td>Wash-out rate</td>
<td></td>
<td>.121</td>
<td>.210</td>
</tr>
<tr>
<td>SPECT TDS</td>
<td></td>
<td>0.701</td>
<td>.0001</td>
</tr>
<tr>
<td>LVEF</td>
<td></td>
<td>-.122</td>
<td>.272</td>
</tr>
</tbody>
</table>

EAT, epicardial adipose tissue; $^{123}$I-MIBG, iodine-123 meta-iodobenzylguanidine; H/M, heart to mediastinum ratio; TDS, total defect score; LVEF, left ventricular ejection fraction.

**Online Table II. Correlation between LVEF and cardiac $^{123}$I-MIBG planar and SPECT data.**

<table>
<thead>
<tr>
<th>$^{123}$I-MIBG planar and SPECT data</th>
<th>LVEF</th>
<th>Pearson</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early H/M</td>
<td></td>
<td>0.179</td>
<td>.106</td>
</tr>
<tr>
<td>Late H/M</td>
<td></td>
<td>0.388</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Wash-out rate</td>
<td></td>
<td>-0.146</td>
<td>.187</td>
</tr>
<tr>
<td>SPECT TDS</td>
<td></td>
<td>-0.263</td>
<td>.051</td>
</tr>
</tbody>
</table>

LVEF, left ventricular ejection fraction; $^{123}$I-MIBG, iodine-123 meta-iodobenzylguanidine; H/M, heart to mediastinum ratio; TDS, total defect score.
Online Table III. Heart rate variability data on cardiac parasympathetic activity in HF patients

<table>
<thead>
<tr>
<th>HRV parameters</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>pNN50, %</td>
<td>13.05±17.23</td>
</tr>
<tr>
<td>rMMSD, msec</td>
<td>40.08±27.40</td>
</tr>
<tr>
<td>HF, msec²</td>
<td>218.96±272.48</td>
</tr>
</tbody>
</table>

pNN50, percentage of successive normal sinus RR intervals >50 ms; rMSSD, root-mean-square of the successive normal sinus RR interval difference; HF, high frequency oscillation

Online Table IV. Correlation between EAT and cardiac parasympathetic activity assessed by HRV

<table>
<thead>
<tr>
<th>EAT</th>
<th>Pearson</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRV parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pNN50</td>
<td>0.102</td>
<td>.678</td>
</tr>
<tr>
<td>rMMSD</td>
<td>0.079</td>
<td>.747</td>
</tr>
<tr>
<td>HF</td>
<td>0.051</td>
<td>.083</td>
</tr>
</tbody>
</table>

EAT, epicardial adipose tissue; HRV, heart rate variability; pNN50, percentage of successive normal sinus RR intervals >50 ms; rMSSD, root-mean-square of the successive normal sinus RR interval difference; HF, high frequency oscillation